Category 1 Winner David Kuraguntla
Wearable Device for Continuous, Non-Invasive Monitoring of Vascular Access Health and Fluid Status in Hemodialysis Patients
GraftWorx has created and clinically validated an end-to-end remote monitoring platform for proactive and noninvasive fluid management and arteriovenous access monitoring in hemodialysis patients. This platform comprises a novel multi-modal sensor device in an ultra-low-power flexible package, a seamless & secure data transmission pathway, and clinical alert generation via proprietary algorithms. The GraftWorx system has been validated on 120 patients across 3 clinical studies, has been granted 4 patents and has 23 patents pending, and we expect to receive FDA clearance in early 2020. We have closed clinical partnerships with prospective dialysis customers who manage 50,000 patients.